ReviewExpert review of anticancer therapy2013
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.
Review in Expert review of anticancer therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.Cancer medicine · 2018Trial
- Study of the association between HDAC8, SIRT1, and P53 gene expression with drug resistance in chronic myeloid leukemia patients.BMC cancer · 2025Article
- REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity.Leukemia · 2024Article
- The roles of KLHL family members in human cancers.American journal of cancer research · 2022Review
- GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.Autophagy · 2019Article
- Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.The Journal of molecular diagnostics : JMD · 2019Article
- Comprehensive kinome NGS targeted expression profiling by KING-REX.BMC genomics · 2019Article
- Stem cell fate in cancer growth, progression and therapy resistance.Nature reviews. Cancer · 2018Review
- p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib.Diseases (Basel, Switzerland) · 2018Article
- Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib.Cancer medicine · 2017Article
- Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase.Targeted oncology · 2017Article
- Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia.Blood research · 2017Article
- Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia.Blood advances · 2016Article
- Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia.Cardio-oncology (London, England) · 2015Review
- Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia.Leukemia research and treatment · 2015Review
- ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.International journal of hematology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chronic myeloid leukemia (CML) is a hematologic neoplasm with a progressive, ultimately terminal, disease course. In most cases, CML arises owing to the aberrant formation of a chimeric gene for a constitutively active tyrosine kinase. Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. New tyrosine kinase inhibitors continue to improve the management of CML, offering alternative options for those resistant to or intolerant of standard tyrosine kinase inhibitors. Here we review the pathobiology of CML and explore emerging strategies to optimize the management of chronic-phase CML, particularly first-line treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.